52 studies found for:    "Acinic cell carcinoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Acinic cell carcinoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Combination Chemotherapy With or Without Oregovomab Followed By Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Biological: oregovomab;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Drug: fluorouracil
2 Not yet recruiting Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage I-III Pancreatic Cancer
Interventions: Drug: metformin hydrochloride;   Radiation: stereotactic radiosurgery
3 Completed
Has Results
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IV Pancreatic Cancer
Interventions: Drug: bortezomib;   Drug: carboplatin;   Other: laboratory biomarker analysis
4 Active, not recruiting Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: falimarev;   Biological: inalimarev;   Biological: sargramostim;   Other: laboratory biomarker analysis
5 Not yet recruiting High-Dose Radiation Therapy Versus Standard Care in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Radiation: intensity-modulated radiation therapy;   Radiation: 3-dimensional conformal radiation therapy;   Drug: capecitabine;   Other: laboratory biomarker analysis
6 Recruiting Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Radiation: hyperfractionated radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiosurgery;   Procedure: diffusion-weighted magnetic resonance imaging
7 Recruiting Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer
Interventions: Drug: porfimer sodium;   Procedure: endoscopic ultrasonography;   Procedure: photodynamic therapy;   Drug: gemcitabine hydrochloride
8 Withdrawn Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Recurrent Pancreatic Cancer;   Stage IV Breast Cancer;   Stage IV Pancreatic Cancer
Interventions: Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: pharmacological study;   Biological: tumor-homing peptide iRGD
9 Recruiting Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of Unknown Primary;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Duct Cell Adenocarcinoma of the Pancreas;   Intestinal Adenocarcinoma of the Stomach;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Carcinoma of Unknown Primary;   Metastatic Extrahepatic Bile Duct Cancer;   Mixed Adenocarcinoma of the Stomach;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Newly Diagnosed Carcinoma of Unknown Primary;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Gallbladder Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Gallbladder Cancer;   Stage IVB Rectal Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
10 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Recruiting Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: dasatinib;   Drug: erlotinib hydrochloride
12 Completed Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: triapine
13 Completed Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: paclitaxel;   Drug: bryostatin 1;   Other: pharmacological study
14 Recruiting Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alisertib;   Drug: gemcitabine
15 Not yet recruiting Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: ceritinib;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Recruiting Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: 5-fluorouracil;   Drug: capecitabine;   Radiation: radiation;   Procedure: surgery;   Drug: gemcitabine  hydrochloride
17 Active, not recruiting Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib;   Drug: sirolimus;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18
18 Completed Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sorafenib tosylate;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
19 Active, not recruiting Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: dasatinib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Other: immunohistochemistry staining method
20 Active, not recruiting Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: wild-type reovirus;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years